Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology/Complications

Type 1 Diabetes Is Associated With Increased Cyclooxygenase- and Cytokine-Mediated Inflammation

  1. Samar Basu, MSC, PHD1,
  2. Anders Larsson, MD, PHD2,
  3. Johan Vessby, MD1,
  4. Bengt Vessby, MD, PHD1 and
  5. Christian Berne, MD, PHD3
  1. 1Section of Geriatrics and Clinical Nutrition Research, Uppsala University, Uppsala, Sweden
  2. 2Section of Clinical Chemistry, Uppsala University, Uppsala, Sweden
  3. 3Section of Internal Medicine, Faculty of Medicine, Uppsala University, Uppsala, Sweden
  1. Address correspondence and reprint requests to Samar Basu, PhD, Section of Geriatrics and Clinical Nutrition Research, Faculty of Medicine, Uppsala University, P.O. Box 609, SE-751 25 Uppsala, Sweden. E-mail: samar.basu{at}pubcare.uu.se
Diabetes Care 2005 Jun; 28(6): 1371-1375. https://doi.org/10.2337/diacare.28.6.1371
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE—The extent of involvement of cyclooxygenase (COX)-mediated inflammation in type 1 diabetes is unknown, and the association between the COX- and cytokine-mediated inflammatory responses in type 1 diabetes is not fully understood.

RESEARCH DESIGN AND METHODS—Plasma high-sensitivity C-reactive protein (CRP), 24-h urinary and plasma 15-keto-dihydro-prostaglandin F2α (a metabolite of prostaglandin F2α [PGF2α] and an indicator of COX-mediated inflammation), serum amyloid protein A (SAA), and interleukin (IL)-6 (indicators of inflammation) were measured in 38 subjects with type 1 diabetes and 41 healthy age- and sex-matched control subjects.

RESULTS—The inflammatory indicators (urinary 15-keto-dihydro-PGF2α, P < 0.01; IL-6, P < 0.04) were increased in men with diabetes. CRP and SAA did not show any significant difference between the diabetic and the control subjects. Urinary levels of 15-keto-dihydro-PGF2α correlated with the degree of glycemic control, HbA1c (r = 0.42, P < 0.0005). No correlation was found between the duration of diabetes and the inflammatory biomarkers or metabolic measurements.

CONCLUSIONS—These results suggest that an early low-grade inflammatory process reflected by elevated levels of PGF2α and IL-6 is involved in type 1 diabetes. Thus, both COX- and cytokine-mediated inflammatory pathways are significantly related to type 1 diabetes.

  • COX, cyclooxygenase
  • CRP, C-reactive protein
  • IL, interleukin
  • PGF2α, prostaglandin F2α
  • SAA, serum amyloid A

Compared with a control population, type 1 diabetes is associated with an increased risk of microvascular complications and premature atherosclerosis (1). Atherosclerosis is considered to be in part a consequence of a chronic low-grade inflammation (2,3), and it has been suggested that atherosclerosis and diabetes might share the mutual inflammatory phenomenon hypothesis (4,5). In recent years inflammation has been suggested to be involved in type 1 diabetes (6). Blood levels of interleukin (IL)-6 have been shown to be normal (7) or higher (8,9) in type 1 diabetic patients compared with levels in control subjects. Cytokine-mediated acute-phase proteins have also been studied (9,10), but their role in diabetes without atherosclerosis is inconclusive.

An ongoing inflammatory process can lead to gradual cell destruction followed by arachidonic acid release and its bioconversion by cyclooxygenase (COX) to various bioactive prostaglandins. Prostaglandin F2α (PGF2α) is a potent vasoconstrictive compound (11). Moreover, prostaglandins are important mediators of the inflammatory process (12,13), and 15-keto-dihydro-PGF2α, a major metabolite of PGF2α, has been shown to be a reliable indicator of in vivo COX-mediated inflammation (14,15). In a recent study, 15-keto-dihydro-PGF2α, high-sensitivity C-reactive protein (CRP), and serum amyloid protein A (SAA), which are all inflammatory indicators, were increased in men with type 2 diabetes in a population-based cross-sectional study (16). Cytokine-mediated CRP and SAA were more closely related to obesity and insulin than to the diagnosis of diabetes, suggesting that COX-mediated low-grade inflammatory activity is a central phenomenon in elderly type 2 diabetic patients. The association between type 1 diabetes and COX-mediated PGF2α formation is unknown.

Thus, the goal of this study was to investigate the association between type 1 diabetes and COX-mediated PGF2α, inflammatory cytokine IL-6– and cytokine-mediated CRP, and SAA in type 1 diabetic subjects and compare it with age-matched healthy control subjects.

RESEARCH DESIGN AND METHODS

Subjects with type 1 diabetes, all attending the clinic of diabetes and endocrinology at the Uppsala University Hospital, were asked to participate in the study. A total of 38 diabetic subjects accepted, of whom 36 were using meal-related rapid-acting insulin combined with bedtime NPH insulin, and two were treated with insulin pumps. Their mean duration of diabetes was 16.1 ± 10.3 years. A total of 41 apparently healthy nondiabetic control subjects were recruited from the staff of the Uppsala University Hospital and among medical students. The participants were between 20 and 45 years of age. The two groups were well matched for sex, age, and BMI. Clinical characteristics are shown in Table 1. None of the included subjects was pregnant or had a history of malignancy, liver disease, untreated hypothyroidism, alcohol abuse, intercurrent diseases, or use of lipid-lowering drugs. According to a self-administrated questionnaire, eight of the diabetic subjects and four of the control subjects reported daily smoking of cigarettes. Three diabetic and five control subjects reported that they took multivitamin supplements regularly.

Macrovascular disease was defined as clinical history of angina or myocardial infarction. Microalbuminuria was defined as a urinary albumin excretion rate of 30–300 mg/24 h and macroalbuminuria as >300 mg/24 h, respectively, in more than one urine collection. Proliferative retinopathy was considered present if observed by fundus photography, which all diabetic subjects had undergone, or if there was a history of laser treatment. Peripheral neuropathy was defined as the loss of ankle reflexes and/or the loss of lower-limb sensation to light touch (monofilament) or vibration on clinical testing. Four subjects had signs of multiple microangiopathic complications, here defined as a clinical history of retinopathy, neuropathy, and/or micro- or macroalbuminuria. One type 1 diabetic subject had a history of microalbuminuria and one patient had a history of macroalbuminuria. Three of the subjects had a history of proliferative retinopathy. Six diabetic subjects were using either ACE inhibitors or an angiotensin receptor antagonist. Informed consent was obtained from all participating subjects, and the study was approved by the ethical committee at the Medical Faculty of Uppsala University.

Sample collection and handling

Blood samples from all 79 participants were collected, after a 12-h overnight fast, into Vacutainer tubes containing Na-heparin, EDTA, or buffered sodium-citrate. HbA1c was measured in fresh blood samples taken on the morning of the study.

The blood was stored on ice and thereafter centrifuged at 3,000 rpm for 10 min at 4 C°, and the plasma was separated. For determination of cholesterol and triglycerides, blood was collected into Vacutainer tubes without any addition and left to coagulate for 2 h. After low-speed centrifugation for 10 min, the serum was separated. One aliquot was stored in 4 C° before lipid analysis. A 24-h urine collection was delivered by 76 of the 79 participants at the time of the blood sampling. Urine samples were stored at −70°C until analysis for 15-keto-dihydro-PGF2α and albumin were performed.

Biochemical assays (inflammatory biomarkers)

Radioimmunoassay of 15-keto-dihydro-PGF2α.

The 24-h urinary and plasma samples were analyzed for 15-keto-dihydro-PGF2α by a radioimmunoassay at our laboratory, as previously described by Basu (14). In brief, the cross-reactivity of the antibody with PGF2α; 15-keto-PGF2α; PGE2; 15-keto-13,14-dihydro-PGE2; 8-iso-15-keto-13,14-dihydro-PGF2α; 11β-PGF2α; 9β-PGF2α; thromboxane B2; and 8-iso-PGF3α was 0.02, 0.43, <0.001, 0.5, 1.7, <0.001, <0.001, <0.001, and 0.01%, respectively. The detection limit was 45 pmol/l. The levels of 15-keto-dihydro-PGF2α in urine were adjusted for creatinine by division with the urinary creatinine concentration.

Assay of high-sensitivity CRP and SAA.

High-sensitivity CRP and SAA measurements were performed by latex-enhanced reagent (Dade Behring, Deerfield, IL), using a BN ProSpec analyzer (Dade Behring). The intra-assay coefficient of variation (CV) of the CRP method was 1.4% at both 1.23 and 5.49 mg/l, and the intra-assay CV of the SAA method was 5.9% at 12.8 mg/l and 3.2% at 81.7 mg/l.

Measurement of IL-6.

High-sensitivity IL-6 was analyzed by an enzyme-linked immunosorbent assay kit (IL-6 HS; R&D Systems, Minneapolis, MN). Samples and standards were pipetted in a microtiter plate coated with monoclonal antibody against IL-6. After incubation and washing, the enzyme substrate solution was pipetted and followed by the addition of anti–IL-6 antibody. The color reaction was proportional to the bound IL-6. The total CV of the method was 7%, and the interassay CV was 5%.

Other biochemical assays.

Serum triglycerides and cholesterol were measured by enzymatic methods using IL Test Cholesterol Triander’s Method 181618-80 and IL Test Enzymatic-Colorimetric Method 181709-00 for use in the Monarch apparatus (Instrumentation Laboratory, Lexington, MA). Apolipoprotein B–containing lipoproteins were precipitated with a sodium phosphotungstate, and magnesium chloride solution (17) LDLs were calculated according to Friedewald et al. (18). Albumin in urine was analyzed by rate nephelometry on an Array protein system (Beckman Instruments, Brea, CA). The assay was performed according to the recommendations by the manufacturer. HbA1c level was measured by automated high-performance liquid chromatography (reference range 3.5–5.0%) (19).

Statistical analysis

Unpaired Student’s t test was used to compare the two groups. Logarithmic transformations were applied on non–normally distributed parameters. The nonparametric Wilcoxon test was used on parameters, which were still not normally distributed after transformation. Linear relationships between variables were evaluated by Pearson’s correlation test. Spearman correlation was used with parameters not normally distributed.

RESULTS

Basic metabolic variables

The urinary albumin excretion rate (means ± SD) was significantly higher among the diabetic subjects than the control subjects (2.23 ± 5.83 vs. 0.32 ± 0.49 mg/h, P < 0.05) (Table 1). In a subgroup analysis excluding patients with blood pressure–lowering drugs (n = 6), type 1 diabetic patients had significantly higher urinary albumin excretion rates than control subjects (10.8 ± 11.5 vs. 0.56 ± 1.2 mg/h, P < 0.01). No differences were noted in serum lipid and lipoprotein levels between diabetic and control subjects, except for serum triglycerides, which were higher in the control group than in the type 1 diabetic group (0.82 ± 0.61 vs. 1.07 ± 0.54 mmol/l, P < 0.05) (Table 2). Exclusion of subjects who were smokers and/or subjects who were taking antioxidant supplements from both groups did not change any of the relationships between diabetic and control subjects, except for serum triglycerides, which showed no significant difference after the exclusion (0.82 ± 0.68 vs. 0.99 ± 0.53 mmol/l, NS).

Levels of 15-keto-dihydro-PGF2α (indicator of COX-mediated inflammation)

Type 1 diabetic patients had significantly higher levels (P < 0.01) of urinary 15-keto-dihydro-PGF2α than control subjects (Table 3). In a subgroup analysis excluding patients with blood pressure–lowering drugs (n = 6), type 1 diabetic patients had significantly higher levels of urinary 15-keto-dihydro-PGF2α than control subjects (P = 0.02). Type 1 diabetic patients with blood pressure–lowering drugs had no difference in urinary 15-keto-dihydro-PGF2α compared with the normotensive diabetic patients (310 ± 90 vs. 310 ± 110 pmol/mmol creatinine). There was no difference in the levels of 15-keto-dihydro-PGF2α between the subjects who have or do not have microvascular complications (microalbuminuria) (data not shown).

Levels of IL-6, CRP, and SAA (indicators of cytokine-mediated inflammation)

Type 1 diabetic patients had significantly (P < 0.04) higher plasma levels of IL-6 than control subjects (Table 3). Neither CRP nor SAA differed significantly between the diabetic patients and the control subjects (Table 3). In a subgroup analysis excluding patients with blood pressure–lowering drugs (n = 6), type 1 diabetic patients had significantly higher levels of IL-6 than control subjects (P = 0.04). Type 1 diabetic patients with blood pressure–lowering drugs had no difference in the levels of IL-6, CRP, and SAA compared with the normotensive diabetic patients, and there was no difference in the levels of IL-6, CRP, and SAA between the subjects who have or do not have microvascular complications (microalbuminuria) (data not shown).

Correlation between inflammatory indicators and metabolic measurements

Urinary levels of 15-keto-dihydro-PGF2α correlated with the degree of glycemic control, as reflected by HbA1c (r = 0.42, P < 0.0005) (Fig. 1). Plasma levels of 15-keto-dihydro-PGF2α were positively correlated with IL-6 (r = 0.24, P < 0.04). No correlation was found between the duration of diabetes and any measured inflammatory or metabolic parameters.

CONCLUSIONS

In this case-control study, we compared type 1 diabetic patients with nondiabetic control subjects. The group was relatively heterogeneous with regard to duration of diabetes and diabetes-related complications, representing a random sample of an average Swedish diabetic population. With few exceptions type 1 diabetic subjects attend hospital clinics, whereby the sample can be considered to be population based in the hospital catchment area (population 220,000).

This study shows that COX-mediated urinary 15-keto-dihydro-PGF2α and plasma IL-6 levels were significantly higher in patients with type 1 diabetes compared with healthy control subjects. Plasma levels of 15-keto-dihydro-PGF2α and IL-6 were positively correlated (r = 0.24, <0.04). Although this correlation is not very strong, it is of potential biological importance because the pathways of formation of PGF2α and IL-6 are novel and different. Furthermore, there was a fair degree of correlation (r = 0.42, P < 0.0005) between urinary levels of 15-keto-dihydro-PGF2α and HbA1c. Previously, we did not find any significant association between the inflammatory biomarkers and HbA1c levels in elderly men with type 2 diabetes (16). These subjects often suffer from long-lasting atherosclerotic macrovascular damage, in contrast to relatively young, well-controlled type 1 diabetic patients in this study without signs of any macrovascular complications (Table 1). Type 1 diabetic patients in this study do not show any signs of macrovascular disease, which is often related to inflammation, and it is reasonable to assume that it is easier to show a significant relationship between hyperglycemia and the levels of inflammatory biomarker PGF2α metabolite in this group.

We did not find any difference in the inflammatory biomarkers in patients with microvascular complications compared with those who do not have microvascular complications. Furthermore, we did not find any difference in the inflammatory biomarkers in type 1 diabetic patients who were treated with blood pressure–lowering drugs compared with the normotensive patients. It is known that angiotensin II may stimulate IL-6 and other inflammatory biomarkers (20,21). Thus, it is possible that administration of angiotensin II blockers, as given to six patients, would reduce the levels of inflammatory biomarkers. This might explain why there is no significant difference in inflammatory biomarkers among blood pressure–treated and nontreated patients.

This study is the first to report increased levels of COX-mediated PGF2α as measured by urinary 15-keto-dihydro-PGF2α in type 1 diabetic patients compared with control subjects. Prostaglandins are well-known mediators of inflammation, and 15-keto-dihydro-PGF2α, a major metabolite of bioactive PGF2α, is a potent indicator of in vivo inflammatory processes (14,15,22,23). Thus, the results from this study suggest ongoing COX-mediated low-grade inflammatory processes among patients with type 1 diabetes. PGF2α is shown to be a potent vasoconstrictive compound (11), and this might have further contributed to the pathogenesis of diabetes complications via decreased blood flow (24) and endothelium dysfunction (25). Recently, it has been shown that 11-dehydro-thromboxane B2, a metabolite of thromboxane A2 and a COX-mediated product primarily formed in the thrombocytes, is associated with type 1 diabetes (26). This might reflect that PGF2α, being a major product of arachidonic acid through COX, could possibly induce platelet adhesion and aggregation, as has been demonstrated for an isomer of PGF2α, 8-iso-PGF2α (27,28). Furthermore, we have also shown that a significant correlation exists between the glycemic status as reflected by HbA1c and the urinary levels of 15-keto-dihydro-PGF2α.

This study also demonstrates enhanced levels of IL-6 in type 1 diabetic patients, which further indicates that type 1 diabetes is associated with an increased cytokine-mediated inflammatory response, which is corroborated by other studies (6,8). Furthermore, the levels of IL-6 correlated with COX-mediated PGF2α metabolite. Cytokines have earlier been shown to stimulate prostaglandin formation in fibroblasts through induction of COXs (29). Both the cytokines and COXs are activated in the cells through the nuclear factor-κB pathway under inflammatory conditions elicited by various stress factors, such as reactive oxygen species and viral and bacterial infection (30). Together, these results indicate that the inflammatory mechanism might be responsible for enhanced atherogenesis and is possibly associated with common vascular complications among type 1 diabetic patients. Although these patients have an acceptable average glycemic status, it did not account for a lower inflammatory response, as reflected by increased levels of cytokines and cytokine- and COX-mediated products.

Acetylsalicylic acid is known to reduce cardiovascular risk through affecting inflammatory processes (2). Intake of low-dose aspirin or other anti-inflammatory drugs is considered to be effective as secondary prophylaxis of cardiovascular diseases and primary prophylaxsis of myocardial infarction (31). Aspirin inhibits COXs and thus the biosynthesis of parent prostaglandins and thromboxanes that are related to inflammation (12,32,33). Recently, it has also been shown that high doses of salicylates specifically inhibit the function of I-κ-kinase-β, a key protein involved in the regulation of inflammation that interferes with insulin signaling and contributes to both insulin resistance and diabetes (34). The current study shows that basal levels of PGF2α and IL-6 are increased among type 1 diabetic patients, involving both COX and cytokine pathways. Thus, it is tempting to speculate that acetylsalicylic acid might have some effect in reducing the inflammatory condition in this patient group, but this has yet to be determined.

In conclusion, this study demonstrates an involvement of low-grade cytokine- and COX-mediated inflammation in type 1 diabetes. Furthermore, we found a significant correlation between the levels of PGF2α metabolite and the degree of metabolic control, which suggests a potential link to fatty acid oxidation and insulin resistance. Thus, hyperglycemia is associated with increased production of these important inflammatory compounds. The association of these inflammatory biomarkers with type 1 diabetes indicates that an important association exists between type 1 diabetes and the future possibility of development of atherosclerosis.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Correlation between the urinary PGF2α metabolite 15-keto-dihydro-PGF2α (nmol/mmol creatinine) and HbA1c (r = 0.42, P < 0.0005).

View this table:
  • View inline
  • View popup
Table 1—

Baseline clinical characteristics in type 1 diabetic and control subjects

View this table:
  • View inline
  • View popup
Table 2—

Serum lipid concentrations in type 1 diabetic and control subjects

View this table:
  • View inline
  • View popup
Table 3—

Inflammatory biomarkers in type 1 diabetes and control subjects

Acknowledgments

This study received support from the Swedish Society of Medicine, the Foundation for Geriatric Research, the Thuréus Foundation, the Henning and Gösta Ankarstrand Foundation, and the Swedish Nutrition Foundation.

We are grateful to Barbro Simu, Siv Tengblad, and Eva Sejby for excellent technical assistance. Rawya Mohsen is acknowledged for statistical analyses.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted March 3, 2005.
    • Received October 28, 2004.
  • DIABETES CARE

References

  1. ↵
    Deckert T, Poulsen JE, Larsen M: Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia 14: 363–370, 1978
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Ridker PM, Cushman M, Stampfer MJ, Tracey RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979, 1997
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appelby P, Gallimas JR, Peppys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321:199–204, 2000
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Stern MP: Diabetes and cardiovascular disease: the “common soil” hypothesis (Review). Diabetes 44:369–374, 1995
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Pradhan AD, Ridker PM: Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23:831–834, 2002
    OpenUrlFREE Full Text
  6. ↵
    Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G: Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications (Letter). Diabetes Care 24:956–957, 2001
    OpenUrlFREE Full Text
  7. ↵
    Kulseng B, Vatten L, Espevik T: Soluble tumor necrosis factor receptors in sera from patients with insulin-dependent diabetes mellitus: relations to duration and complications of disease. Acta Diabetol 36:99–105, 1999
    OpenUrlCrossRefPubMed
  8. ↵
    Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jesperssen L: Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 81:485–490, 1996
    OpenUrlCrossRefPubMed
  9. ↵
    McMillan DE: Increased levels of acute-phase serum proteins in diabetes. Metabolism 38:1042–1046, 1989
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23:1835–1839, 2000
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Bergström S: Prostaglandins: members of a new hormonal system: these physiologically very potent compounds of ubiquitous occurrence are formed from essential fatty acids. Science 157:382–391, 1967
    OpenUrlFREE Full Text
  12. ↵
    Vane JR: Prostaglandins as mediators of inflammation. Adv Prostaglandin Thromboxane Res 2:791–801, 1976
    OpenUrlPubMedWeb of Science
  13. ↵
    Willoughby DA: Human arthritis applied to animal models: towards a better therapy. Ann Rheum Dis 34:471–478, 1975
    OpenUrlFREE Full Text
  14. ↵
    Basu S: Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2alpha: an index for inflammation via cyclooxygenase catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 58:347–352, 1998
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Mutschler DK, Eriksson MB, Wikstrom BG, Lind L, Larsson A, Bergren-Kiiski R, Larange A, Norgren A, Basu S: Microdialysis-evaluated myocardial cyclooxygenase-mediated inflammation and early circulatory depression in porcine endotoxemia. Crit Care Med 31:1780–178, 2003
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Helmersson J, Vessby B, Larsson A, Basu S: Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in elderly men, Circulation 109:1729–1734, 2004
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Seigler L, Wu WT: Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 27:838–841, 1981
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Friedewald WT, Levi RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18:499–502, 1972
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Jeppsson JO, Jerntorp P, Sundqvist G, Englund H, Nylund V: Measurement of hemoglobin A1c by a new liquid-chromatography assay: methodology, clinical utility, and relation to glucose tolerance. Clin Chem 32:1867–1872, 1986
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K: Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 44:264–270, 2004
    OpenUrlAbstract/FREE Full Text
  21. ↵
    da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX: Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178:9–17, 2005
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Basu S, Eriksson MK: Oxidative injury and survival during endotoxemia. FEBS Lett 438:159–160, 1998
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Basu S, Nozari A, Liu XL, Rubertsson S, Wiklund L: Development of a novel biomarker of free radical damage in reperfusion injury after cardiac arrest. FEBS Lett 470:1–6, 2000
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Baron AD, Johnson A, Fineberg N, Brechtel G, Steinberg H: Sceletal muscle blood flow independently modulates insulin-mediated glucose uptake. J Clin Invest 266:E248–E253, 1994
    OpenUrl
  25. ↵
    Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 97:2601–2610, 1996
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C: Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107:3199–3203, 2003
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Minuz P, Andrioli G, Degan M, Gaino S, Ortolani R, Tommasoli R, Zuliani V, Lechi A, Lechi C: The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 18:1248–1256, 1998
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Davi G, Catalano I, Averna M, Notartartolo A, Strano A, Ciabattoni G, Patrono C: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769–1774, 1990
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Raz A, Wyche A, Siegel N, Needleman P: Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 263:3022–3028, 1988
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Senftleben U, Karin M: The IKK/NF-kappaB pathway. Crit Care Med 30:S18–S26, 2002
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trials’ Collaboration. BMJ 308:81–106, 1994
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235, 1971
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Helmersson J, Vessby B, Larsson A, Basu S: Cyclooxygenase-mediated prostaglandin F(2alpha) is decreased in an elderly population treated with low-dose aspirin. Prostaglandins Leukot Essent Fatty Acids 72:227–233, 2005
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677, 2001
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes Care: 28 (6)

In this Issue

June 2005, 28(6)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Type 1 Diabetes Is Associated With Increased Cyclooxygenase- and Cytokine-Mediated Inflammation
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Type 1 Diabetes Is Associated With Increased Cyclooxygenase- and Cytokine-Mediated Inflammation
Samar Basu, Anders Larsson, Johan Vessby, Bengt Vessby, Christian Berne
Diabetes Care Jun 2005, 28 (6) 1371-1375; DOI: 10.2337/diacare.28.6.1371

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Type 1 Diabetes Is Associated With Increased Cyclooxygenase- and Cytokine-Mediated Inflammation
Samar Basu, Anders Larsson, Johan Vessby, Bengt Vessby, Christian Berne
Diabetes Care Jun 2005, 28 (6) 1371-1375; DOI: 10.2337/diacare.28.6.1371
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort
  • Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes
  • High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
Show more Pathophysiology/Complications

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.